Back to Menu
Multiple myeloma is a malignant plasma cell disorder in which clonal plasma cells expand in the bone marrow and produce a monoclonal immunoglobulin (M-protein) and/or free light chains. This can lead to end-organ damage such as lytic bone lesions, anemia, renal dysfunction, and hypercalcemia.
1. Immunoglobulin subtype
Includes IgG, IgA, IgD, IgE, and light-chain myeloma, among others.
2. Cytogenetic risk stratification
Classified into standard-risk and high-risk disease based on genetic abnormalities, which guides prognosis and treatment intensity.
3. Disease activity classification
Includes smoldering multiple myeloma and active (symptomatic) multiple myeloma.
4. Staging systems
Durie–Salmon staging and the International Staging System (ISS) are used to assess disease burden and severity.
5. Features of light-chain myeloma
Produces only light chains; routine serum protein electrophoresis may miss cases, so dedicated free light chain testing is important.
1. Genetic susceptibility
Familial clustering and certain genetic alterations may increase risk.
2. Age
Incidence rises with age; the median age at diagnosis is approximately 65 years.
3. Chronic antigenic stimulation
Long-term infections or autoimmune conditions may be associated with increased risk.
4. Environmental exposures
Associations have been reported with ionizing radiation, organic solvents, and certain pesticides.
5. Obesity and chronic inflammation
Obesity and inflammatory states are potential contributing risk factors.
1. Regular check-ups
High-risk individuals should consider periodic blood tests to detect abnormalities early.
2. Reduce harmful exposures
Minimize unnecessary radiation exposure and contact with hazardous chemicals where possible.
3. Healthy lifestyle
Maintain a healthy weight, exercise regularly, and support overall immune health.
4. Seek medical evaluation early
Prompt assessment is recommended for persistent bone pain, unexplained anemia-related symptoms, recurrent infections, or renal function changes.
5. Adherence to standardized care
Following physician-recommended treatment and surveillance improves outcomes and supports long-term disease control.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that multiple myeloma can cause severe skeletal complications, renal failure, and infections, posing a serious threat to life. With advances in novel agents and therapeutic strategies, survival has improved substantially. Early diagnosis, standardized treatment, and longitudinal management are key to improving prognosis. High-risk populations are advised to undergo regular screening, and multidisciplinary collaboration can provide more comprehensive care and better quality of life.
Multiple myeloma is a malignant plasma cell disorder in which clonal plasma cells expand in the bone marrow and produce a monoclonal immunoglobulin (M-protein) and/or free light chains. This can lead to end-organ damage such as lytic bone lesions, anemia, renal dysfunction, and hypercalcemia.
1. Immunoglobulin subtype
Includes IgG, IgA, IgD, IgE, and light-chain myeloma, among others.
2. Cytogenetic risk stratification
Classified into standard-risk and high-risk disease based on genetic abnormalities, which guides prognosis and treatment intensity.
3. Disease activity classification
Includes smoldering multiple myeloma and active (symptomatic) multiple myeloma.
4. Staging systems
Durie–Salmon staging and the International Staging System (ISS) are used to assess disease burden and severity.
5. Features of light-chain myeloma
Produces only light chains; routine serum protein electrophoresis may miss cases, so dedicated free light chain testing is important.
1. Genetic susceptibility
Familial clustering and certain genetic alterations may increase risk.
2. Age
Incidence rises with age; the median age at diagnosis is approximately 65 years.
3. Chronic antigenic stimulation
Long-term infections or autoimmune conditions may be associated with increased risk.
4. Environmental exposures
Associations have been reported with ionizing radiation, organic solvents, and certain pesticides.
5. Obesity and chronic inflammation
Obesity and inflammatory states are potential contributing risk factors.
1. Regular check-ups
High-risk individuals should consider periodic blood tests to detect abnormalities early.
2. Reduce harmful exposures
Minimize unnecessary radiation exposure and contact with hazardous chemicals where possible.
3. Healthy lifestyle
Maintain a healthy weight, exercise regularly, and support overall immune health.
4. Seek medical evaluation early
Prompt assessment is recommended for persistent bone pain, unexplained anemia-related symptoms, recurrent infections, or renal function changes.
5. Adherence to standardized care
Following physician-recommended treatment and surveillance improves outcomes and supports long-term disease control.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that multiple myeloma can cause severe skeletal complications, renal failure, and infections, posing a serious threat to life. With advances in novel agents and therapeutic strategies, survival has improved substantially. Early diagnosis, standardized treatment, and longitudinal management are key to improving prognosis. High-risk populations are advised to undergo regular screening, and multidisciplinary collaboration can provide more comprehensive care and better quality of life.